| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/01/2004 | EP1451153A1 Nk1 antagonists |
| 09/01/2004 | EP1450872A1 Composition and method for treatment of wounds |
| 09/01/2004 | EP1450858A2 Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist |
| 09/01/2004 | EP1450856A2 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| 09/01/2004 | EP1450855A2 Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| 09/01/2004 | EP1450851A1 Treatment of congestive heart failure |
| 09/01/2004 | EP1450849A2 Methods of treating endometreosis |
| 09/01/2004 | EP1450847A2 Apo2 ligand/trail formulations |
| 09/01/2004 | EP1450842A2 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof |
| 09/01/2004 | EP1450839A2 Method of treating estrogen responsive breast cancer |
| 09/01/2004 | EP1450837A2 Interleukin-1 receptors in the treatment of diseases |
| 09/01/2004 | EP1450836A2 Method for short-term and long-term drug dosimetry |
| 09/01/2004 | EP1450832A2 Lactic acid bacteria and their use for treating and preventing cancer |
| 09/01/2004 | EP1450830A2 Minor histocompatibility antigen ha-1: target antigen for immunotherapy of tumors |
| 09/01/2004 | EP1450824A1 Pharmaceutical composition |
| 09/01/2004 | EP1450821A1 Immunostimulatory oligodeoxynucleotides |
| 09/01/2004 | EP1450820A2 Method for treating or preventing inflammatory diseases |
| 09/01/2004 | EP1450818A2 A method for treating inflammatory bowel disease |
| 09/01/2004 | EP1450817A1 Use of pregnane-diones or diols as neuropathic analgesic agents |
| 09/01/2004 | EP1450813A1 Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorrhagia |
| 09/01/2004 | EP1450811A2 2-aryl pyrrolopyrimidines for a1 and a3 receptors |
| 09/01/2004 | EP1450805A1 Method for the treatment of overactive bladder |
| 09/01/2004 | EP1450799A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| 09/01/2004 | EP1450795A1 Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease |
| 09/01/2004 | EP1450793A2 Hypertonia treatment during the acute phase of a cerebrovascular accident |
| 09/01/2004 | EP1450792A1 Benzazole derivatives for the treatment of scleroderma |
| 09/01/2004 | EP1450791A1 Hydrazonopyrazole derivatives and their use as therapeutics |
| 09/01/2004 | EP1450787A2 Formulations and methods for treatment or amelioration of inflammatory conditions |
| 09/01/2004 | EP1450784A2 Hsp90-inhibiting zearalanol compounds and methods of producing and using same |
| 09/01/2004 | EP1450778A2 Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases |
| 09/01/2004 | EP1450776A1 Compositions and kits comprising a defined boron compound, methods of their preparation, and use and administration thereof |
| 09/01/2004 | EP1450775A2 Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections |
| 09/01/2004 | EP1450766A1 Prolonged release biodegradable microspheres and method for preparing same |
| 09/01/2004 | EP1450764A2 Dopamine agonist formulations for enhanced central nervous system delivery |
| 09/01/2004 | EP1450751A2 Nanoparticle delivery vehicle |
| 09/01/2004 | EP1450666A2 Methods and compositions to treat cardiovascular disease using 139,258,1261,1486,2398,2414,7660,8587,10183,10550,12680,17921,32248,60489 or 93804 |
| 09/01/2004 | EP1337228A4 Compositions for removing human cerumen |
| 09/01/2004 | EP1194138A4 Nutritional supplements |
| 09/01/2004 | EP1165135B1 Methods of screening for compounds modulating fxr receptors |
| 09/01/2004 | EP1131037B1 Process for the manufacture of liquid filled capsules |
| 09/01/2004 | EP1042482B1 Acetyl-coa-carboxylase from candida albicans |
| 09/01/2004 | EP1037529A4 Composition useful for providing one-step surgical preparation and drape |
| 09/01/2004 | EP1027067B1 Use of substances having oxytocin activity for the preparation of medicaments for the treatment of affective pain syndromes |
| 09/01/2004 | EP0944621B1 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists |
| 09/01/2004 | EP0942729B1 Use of nk-1 receptor antagonists for treating stress disorders |
| 09/01/2004 | CN1526261A Mounting arrangement for auxiliary burner or lance |
| 09/01/2004 | CN1526025A Genes expressed in breast cancer as prognostic and therapeutic targets |
| 09/01/2004 | CN1526018A Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus |
| 09/01/2004 | CN1526017A Gene associated with leishmania parasite virulence |
| 09/01/2004 | CN1525979A Bridged bicyclic serine protease inhibitors |
| 09/01/2004 | CN1525974A Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine A2a receptor and their use as medicaments |
| 09/01/2004 | CN1525866A Treatment using neublastin polypeptides |
| 09/01/2004 | CN1525865A Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
| 09/01/2004 | CN1525858A A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent for modulating cholinergic function |
| 09/01/2004 | CN1525851A Abuse-resistant controlled-release opioid dosage form |
| 09/01/2004 | CN1525818A Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation |
| 09/01/2004 | CN1524857A Tartrate salt of a substituted dipeptide as growth hormone secretagogue |
| 09/01/2004 | CN1524583A Use of gene for expressing Notch-ligand in production of medicinal preparations for immunotherapy |
| 09/01/2004 | CN1524579A Composite viscoelastic preparation |
| 09/01/2004 | CN1164760C Tenascin-C nucleic acid ligands |
| 09/01/2004 | CN1164675C Polymeric composition for solubilizing poorly water soluble drugs and process for preparation thereof |
| 09/01/2004 | CN1164579C Thiazole and oxazole derivatives and their pharmaceutical use |
| 08/31/2004 | US6784205 Compounds that modulate the activity of PTP-1B and TC-PTP |
| 08/31/2004 | US6784194 Therapeutic use of a thienylcyclohexylamine derivative |
| 08/31/2004 | US6784166 For the treatment of diseases mediated by the hepatitis c virus |
| 08/31/2004 | US6784161 Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
| 08/31/2004 | US6784153 Identify molecules that can bind to organ or tissue specific markers and, therefore, can home to the organ or tissue; membrane dipeptidase (mdp)-binding homing molecule, which is a molecule that selectively homes to lung endothelium |
| 08/31/2004 | US6783955 Polynucleotides encoding human presenilin variant |
| 08/31/2004 | US6783760 Combined cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| 08/31/2004 | US6783758 Diagnosis and treatment of malignant neoplasms |
| 08/31/2004 | US6783757 Composition and method for increasing exorphin catabolism to treat autism |
| 08/31/2004 | US6783753 Rapidly produces peak plasma concentrations of the compound. |
| 08/31/2004 | US6783751 Method for labeling biopolymers using isotopes |
| 08/27/2004 | CA2458001A1 Regulation of immune responses by manipulation of intermediary metabolite levels |
| 08/26/2004 | WO2004072257A2 Dyrks as modifiers of the apc and axin pathways and methods of use |
| 08/26/2004 | WO2004072027A2 Chemical derivatives binding very specifically with g-quadruplex dna structures and use thereof as a specific anti-cancer agent |
| 08/26/2004 | WO2004071532A1 Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses |
| 08/26/2004 | WO2004071522A1 New pharmaceutical compositions based on anticholinergics and soluble tnf receptor fusion proteins |
| 08/26/2004 | WO2004071519A1 Photosynthetic micro-organisms enriched with biologically-active molecules, preparation method thereof and uses of same |
| 08/26/2004 | WO2004071507A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 08/26/2004 | WO2004071506A1 Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections |
| 08/26/2004 | WO2004071498A1 Use of p-glycoprotein inhibitor surfactants at the surface of a colloidal carrier |
| 08/26/2004 | WO2004071472A1 SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF α,α-TREHALOSE |
| 08/26/2004 | WO2004071435A2 Enhanced Bioavailability Using Laser Resonant Homogenization |
| 08/26/2004 | WO2004071431A2 Method and composition for treating neurodegenerative disorders |
| 08/26/2004 | WO2004071429A2 Lung inflammation treatment |
| 08/26/2004 | WO2004071419A2 Methods and compositions for modulating glutamate transport activity in the nervous system |
| 08/26/2004 | WO2004071413A2 Method and composition for potentiating an opiate analgesic |
| 08/26/2004 | WO2004071391A2 Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders |
| 08/26/2004 | WO2004071384A2 New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
| 08/26/2004 | WO2004071383A2 New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action |
| 08/26/2004 | WO2004071283A2 Use of umbilical cord blood to treat individuals having a disease, disorder or condition |
| 08/26/2004 | WO2004060487A3 Composition for the treatment of hiv or aids |
| 08/26/2004 | WO2004056349A3 Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents |
| 08/26/2004 | WO2004045611A8 Use of a thiazolidinedione for the reduction of side effects of chemotherapy |
| 08/26/2004 | WO2004045509A3 Method of using a cox-2 inhibitor and a 5-ht1a receptor modulator as a combination therapy |
| 08/26/2004 | WO2004041185A3 Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells |
| 08/26/2004 | WO2004039336A3 Use of thiol-based compositions in treating chemotherapeutic agent-induced thrombocytopenia |
| 08/26/2004 | WO2004032826A3 Process for preparing tannate tablet capsule or other solid dosage forms |
| 08/26/2004 | WO2004010936A3 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |